OAS stock: Biggest come back - over 84,900% return

 March 3, 2021

Article written on May 14, 2020, here is the link. 

The noose is tightening

Matt DiLallo (Oasis Petroleum): Cratering crude prices have walloped North Dakota's Bakken shale region. One of the region's largest producers, Whiting Petroleum, has declared bankruptcy, while another leader, Continental Resources, had to shut in nearly all its wells because they were losing money. The region's struggles don't bode well for smaller producers like Oasis Petroleum, especially considering its tightening credit profile.

Because lower oil prices have affected the value of its reserves, Oasis' banks recently slashed the amount of credit they're willing to extend the company from $1.3 billion to $625 million. It already borrowed $487 million on that facility, leaving it with little margin for error.  

On top of that, Oasis has more than $1.8 billion of senior notes outstanding, roughly $800 million of which mature in 2022. Given its tight credit profile and junk-rated credit, the company likely won't be able to refinance that debt.

On a positive note, Oasis does have $110 million in cash and a strong oil hedging program, enabling it to produce free cash flow at current oil pricing. It intends to use all that money to repay debt in hopes of staying afloat. However, if oil prices remain weak, and the company doesn't make enough progress on its debt reduction goal, its banks might cut its borrowing base again this fall. That would likely force it to declare bankruptcy so it can restructure its debt.

Follow up 

March 3, 2021

 

BORR stock: Another OAS? Possible 800 times return?

 John Bromels (Borr Drilling): Offshore rig operator Borr Drilling just released a Q1 financial update and a fleet status report on May 20, and neither one was pretty. 

Of the 30 drillships in the company's fleet at the end of 2019, four have been sold. Another three received early termination notices in May, joining 11 other ships in "stacked" (idle) status. That means that of the company's now-26-ship active fleet, more than half (14) are neither generating revenue nor under contract to do so in the future. 

With $1.8 billion in debt on its books and just $13.2 million in cash, the company is facing a liquidity crisis. In its update, Borr announced it was involved in a "tender processes which might lead to sale of certain modern assets," was negotiating "postponement of certain yard commitments, adjustment in covenants and reduced [amortization] as well as deferring cash interest payments" with creditors and shipyards, and has "received certain waivers from its lenders, including ... interest payment deferrals." On top of that, it reported a Q1 net loss of $87 million. 

Basically, Borr is scrambling to stay afloat (no pun intended) by any means it can, whether that's selling its rigs or renegotiating the terms of its credit. But if the sales don't go through or lenders refuse to extend more generous terms, Borr may have no choice but to declare bankruptcy. 

4 More Oil Stocks That Could Go Bankrupt in 2020

 March 3, 2021

Here is the article.

Oil prices imploded earlier this year, which has decimated many oil stocks. Things have gotten so bad that several have already declared bankruptcy. That trend is likely to continue in the coming months. 

The list of at-risk oil stocks seems to be growing by the day as companies update the market on their deteriorating credit profiles. Four that seem to be likely bankruptcy candidates this year are Borr Drilling (NYSE:BORR), California Resources (NYSE:CRC), Denbury Resources (NYSE:DNR), and Oasis Petroleum (NYSE:OAS). 

Biotech stock: Yahoo -> Finance -> Portfolio | All views | Basic, default, detail, fundamental, holdings, portfolio view

 March 3, 2021

Introduction

I start to work on my biotech portfolio and I like to learn from Yahoo -> finance -> portfolio. 

All views

THC stock experience

Knowledge is power. But I did not have good understanding of THC stock. I sold my position too early. I like to review my experience. 

IMVT stock: 51 shares | $2/ share loss in less than a week | $16/ share -> $14/ share

Yahoo -> finance conversation

 The good news is that majority share holders are institutions. In fact insiders + institutions hold in excess of 100% float -- which means there a a good % of shares short. The short squeeze when it starts will be sweet -- meantime buy the shares shorts are making available on sale.

BTW, for now, their drug is used on 3 indications (TED/MG/WAHA) and they plan to announce its use in 3 new indications starting 3rd quarter 2021. Right now LDL increase is indicated only for TED -- and it is because thyroid and LDL are inter tied. You control thyroid and LDL increase occurs. Once they have more data, they will come out with a treatment regime which caters to the LDL side effects...

Reddit - IMVT

Here is the link. 

very optimistic, this is going one way up.. almost 30 day now FDA will respond with release to proceed the trial. If there were concern FDA could have request more ino..

Read other article say LDL rise is prevalent in all thyroid eye. stock has 8 buy and 1 hold.

INSG stock: 5G stock | 5 year over 700% return | over 28% plunge on March 2, 2021

 Fact 1: down 27.9%

Shares of Inseego (NASDAQ:INSG), a provider of mobile networking gear for 5G and 4G telephony, were slipping today as the company warned that sales growth would slow as the demand for 4G begins to fade.

As of 1:25 p.m. EST, Inseego stock was down 27.9%.

The company delivered another strong round of results for the fourth quarter as it's benefited from the work-from-home shift over the last year.

Revenue jumped 64.4% in the quarter to $86.1 million, beating estimates at $83.8 million. The Internet of Things (IoT) and mobile solutions segment drove the growth once again as demand for its networking hardware was strong. Revenue in that category nearly doubled to $72.1 million, and the company said 5G products accounted for more than 30% of hardware sales in the quarter.

On the bottom line, its adjusted loss per share came in at $0.07, which matched estimates.

CEO Dan Mondor said, "2020 was an epic year for Inseego in every respect, as we launched our groundbreaking 5G products with mobile operators on four continents, shipped our first fixed wireless access products, unveiled a suite of powerful SaaS cloud solutions and posted record revenues."

However, what seemed to spook investors was the company's warning on the earnings call, saying that it saw lower demand from 4G products in 2021, especially in the first half of the year, as it said 2021 would mark a transition from 4G to 5G.

At least three analysts downgraded the stock to hold on the news as it implied that 2021 growth would be slower than expected.

Now what

Management did not give specific guidance for the quarter or the year, but fourth-quarter revenue declined from the previous quarter, indicating that the boost from the work-from-home movement may have peaked. Analysts had been calling for 16% revenue growth in 2021, but they will likely revise that figure downward after the update on 4G demand.

While Inseego still looks to be a smart way to play the 5G revolution, investors should remember that the stock is up a healthy 53% over the last year even after today's slide. Investors looking for more upside will have to be patient at this point.

Fact 2: Five Years Ago You'd Have Earned 758% Returns

Inseego Corp. (NASDAQ:INSG) shareholders have seen the share price descend 21% over the month. But that doesn't change the fact that the returns over the last half decade have been spectacular. Indeed, the share price is up a whopping 758% in that time. So it might be that some shareholders are taking profits after good performance. But the real question is whether the business fundamentals can improve over the long term.

It really delights us to see such great share price performance for investors.

View our latest analysis for Inseego

Inseego isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

For the last half decade, Inseego can boast revenue growth at a rate of 0.2% per year. That's not a very high growth rate considering the bottom line. So shareholders should be pretty elated with the 54% increase per year, in that time. We'll tip our hats to that, any day, but the top-line growth isn't particularly impressive when you compare it to other pre-profit companies. It's not immediately obvious to us why the market has been so enthusiastic about the stock, but a more detailed look at revenue and profit trends might reveal why shareholders are optimistic.

INSG - Fundamentals

Plunged stocks: March 2, 2021

 March 2, 2021

Introduction

It is the best time of the day to spend 30 minutes to go over those plunged stocks, so that I can learn more business and see if there are business opportunity for me to invest. 

Plunged stocks - March 2, 2021

ATNX stock: Share price plunge -54.88%

 ATNX stock - plan to purchase $500 US dollars

Shares of Athenex Inc. plummeted 54.6% on very active afternoon trading Monday, enough to be the biggest decliner listed on major U.S. exchanges, after the Food and Drug Administration said the biopharmaceutical company's New Drug Application (NDA) for its metastatic breast cancer treatment, oral paclitaxel plus encequidar, is not ready for approval in its present form. Trading volume spiked to 40.1 million shares, compared with the full-day average of about 1.1 million shares. The company said earlier that the FDA issued a complete response letter (CRL) expressing concerns of a safety risk to patients, and recommended a new clinical trial be conducted. Separately, the company reported a fourth-quarter net loss that widened to $49.5 million, or 53 cents a share, from $21.7 million, or 28 cents a share, in the year-ago period, wider than the FactSet consensus for a per-share loss of 44 cents. Revenue fell 36.5% to $21.8 million, topping the FactSet consensus of $20.7 million. The stock has lost 55.1% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has climbed 40.2% and the S&P 500 has advanced 32.4%.

Yahoo -> Finance -> conversation

More articles 

Athenex, Inc. (NASDAQ:ATNX) shareholders should be happy to see the share price up 10% in the last quarter. But that doesn't change the fact that the returns over the last three years have been less than pleasing. After all, the share price is down 27% in the last three years, significantly under-performing the market.

Given that Athenex didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last three years, Athenex saw its revenue grow by 42% per year, compound. That's well above most other pre-profit companies. While its revenue increased, the share price dropped at a rate of 8% per year. That seems like an unlucky result for holders. It's possible that the prior share price assumed unrealistically high future growth. Before considering a purchase, investors should consider how quickly expenses are growing, relative to revenue.

Given that Athenex didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

In the last three years, Athenex saw its revenue grow by 42% per year, compound. That's well above most other pre-profit companies. While its revenue increased, the share price dropped at a rate of 8% per year. That seems like an unlucky result for holders. It's possible that the prior share price assumed unrealistically high future growth. Before considering a purchase, investors should consider how quickly expenses are growing, relative to revenue.

OTRK stock: March 1, 2021 -46.35%

OTRK stock - plan to purchase $500 US dollars

Here’s the deal - OTRK gave guidance for FY21 that was, while still almost 25% above FY20 results, was WAY below consensus guidance.

Why? See the PR that pre-announced their results. They lost their largest client. And while I understand OTRK’s justification (this customer focused on reducing costs, not on medical results achieved), it is still their largest client.

Would I be shocked to see $25 in the next week? No. Would I buy a s***-ton if it does? Yes.

Strong opportunity here to rewind the clock a bit, get on board this fast-growing small company. Losing a big customer at this stage hurts, an outsized impact on the immediate bottom line. However looking at the company growth and revenue trajectory, a company in a great spot to help firms worldwide in the post-Covid health issues environment, the short-term loss of revenue will be quickly swallowed up by new and expanded existing business. This will likely be at least 2x current price (2x30s) in a couple quarters... back to January levels by end of 2021 and 120+ by end of 2022.

Also... this is a prime time post-Cigna/MDLive acquisition... for another major insurer to expand into this AI behavioral healthcare space, AMWL to think about acquiring OTRK to better compete with TDOC/LVGO, or would be a savvy move for TDOC to pre-emptively acquire OTRK itself for an accretive addition to merge with LVGO addition. All good for OTRK long term... a fantastic opportunity today! I'm loading up.

CRMD stock: March 1, 2021 -39.87%

 CRMD stock - I plan to purchase $500 dollars 

Shares of CorMedix (NASDAQ:CRMD) were crashing 40.4% as of 12:23 p.m. EST on Monday. The steep decline came after the company announced that the Food and Drug Administration isn't approving CorMedix's Defencath, an antibacterial/antifungal catheter lock, for preventing blood infections associated with the use of catheters in hemodialysis.

So what

Many investors were banking on Defencath receiving a thumbs-up from the FDA. The massive sell-off of the biotech stock today isn't a surprise considering the disappointing news.

The FDA's Complete Response Letter (CRL) mentioned concerns at CorMedix's third-party manufacturing facility but didn't provide details. The agency is also requiring that the company conduct a manual extraction study to show that the volume on the label on vials can be consistently withdrawn from the vials.

There were some positives for CorMedix, though. The FDA didn't request any additional clinical data. It didn't point out any safety or efficacy issues with Defencath. Most important of all, the company still has a path to potential approval.

MNKD stock: Over 29% share price drop - MNKD -29.77%

 MNKD stock - Skip this one 

Yahoo -> Finance -> Conversation

convertible arbitrageurs buy convertible debt and short the underlying common stock. Negative “announcement” effects of convertible bond issue may partly reflect temporary price pressure associated with arbitrage-induced short selling upon convertible bond issuance.

$MNKD
+ Schwab upgrade,
+ $175M bond offering,
+ $100M facility sale/lease-back,
+ royalties commencing EOY,
+ Afrezza Revs climbing, ...

Simply Wall St

Mon., March 1, 2021, 1:47 a.m.

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock market. When you buy and hold the right company, the returns can make a huge difference to both you and your family. For example, the MannKind Corporation (NASDAQ:MNKD) share price rocketed moonwards 350% in just one year. Also pleasing for shareholders was the 92% gain in the last three months. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report. It is also impressive that the stock is up 102% over three years, adding to the sense that it is a real winner.

CRMD stock - I plan to purchase $500 dollars 

Shares of CorMedix (NASDAQ:CRMD) were crashing 40.4% as of 12:23 p.m. EST on Monday. The steep decline came after the company announced that the Food and Drug Administration isn't approving CorMedix's Defencath, an antibacterial/antifungal catheter lock, for preventing blood infections associated with the use of catheters in hemodialysis.

So what

Many investors were banking on Defencath receiving a thumbs-up from the FDA. The massive sell-off of the biotech stock today isn't a surprise considering the disappointing news.

The FDA's Complete Response Letter (CRL) mentioned concerns at CorMedix's third-party manufacturing facility but didn't provide details. The agency is also requiring that the company conduct a manual extraction study to show that the volume on the label on vials can be consistently withdrawn from the vials.

There were some positives for CorMedix, though. The FDA didn't request any additional clinical data. It didn't point out any safety or efficacy issues with Defencath. Most important of all, the company still has a path to potential approval.

Equity research: March 1, 2021 | Plunged stocks - March 1, 2021

 

MNKD stock - Skip this one 

Simply Wall St

Mon., March 1, 2021, 1:47 a.m.

While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock market. When you buy and hold the right company, the returns can make a huge difference to both you and your family. For example, the MannKind Corporation (NASDAQ:MNKD) share price rocketed moonwards 350% in just one year. Also pleasing for shareholders was the 92% gain in the last three months. The company reported its financial results recently; you can catch up on the latest numbers by reading our company report. It is also impressive that the stock is up 102% over three years, adding to the sense that it is a real winner.

CRMD stock - I plan to purchase $500 dollars 

Shares of CorMedix (NASDAQ:CRMD) were crashing 40.4% as of 12:23 p.m. EST on Monday. The steep decline came after the company announced that the Food and Drug Administration isn't approving CorMedix's Defencath, an antibacterial/antifungal catheter lock, for preventing blood infections associated with the use of catheters in hemodialysis.

So what

Many investors were banking on Defencath receiving a thumbs-up from the FDA. The massive sell-off of the biotech stock today isn't a surprise considering the disappointing news.

The FDA's Complete Response Letter (CRL) mentioned concerns at CorMedix's third-party manufacturing facility but didn't provide details. The agency is also requiring that the company conduct a manual extraction study to show that the volume on the label on vials can be consistently withdrawn from the vials.

There were some positives for CorMedix, though. The FDA didn't request any additional clinical data. It didn't point out any safety or efficacy issues with Defencath. Most important of all, the company still has a path to potential approval.

OTRK stock - plan to purchase $500 US dollars

Here’s the deal - OTRK gave guidance for FY21 that was, while still almost 25% above FY20 results, was WAY below consensus guidance.

Why? See the PR that pre-announced their results. They lost their largest client. And while I understand OTRK’s justification (this customer focused on reducing costs, not on medical results achieved), it is still their largest client.

Would I be shocked to see $25 in the next week? No. Would I buy a s***-ton if it does? Yes.

Strong opportunity here to rewind the clock a bit, get on board this fast-growing small company. Losing a big customer at this stage hurts, an outsized impact on the immediate bottom line. However looking at the company growth and revenue trajectory, a company in a great spot to help firms worldwide in the post-Covid health issues environment, the short-term loss of revenue will be quickly swallowed up by new and expanded existing business. This will likely be at least 2x current price (2x30s) in a couple quarters... back to January levels by end of 2021 and 120+ by end of 2022.

Also... this is a prime time post-Cigna/MDLive acquisition... for another major insurer to expand into this AI behavioral healthcare space, AMWL to think about acquiring OTRK to better compete with TDOC/LVGO, or would be a savvy move for TDOC to pre-emptively acquire OTRK itself for an accretive addition to merge with LVGO addition. All good for OTRK long term... a fantastic opportunity today! I'm loading up.

ATNX stock - plan to purchase $500 US dollars

Shares of Athenex Inc. plummeted 54.6% on very active afternoon trading Monday, enough to be the biggest decliner listed on major U.S. exchanges, after the Food and Drug Administration said the biopharmaceutical company's New Drug Application (NDA) for its metastatic breast cancer treatment, oral paclitaxel plus encequidar, is not ready for approval in its present form. Trading volume spiked to 40.1 million shares, compared with the full-day average of about 1.1 million shares. The company said earlier that the FDA issued a complete response letter (CRL) expressing concerns of a safety risk to patients, and recommended a new clinical trial be conducted. Separately, the company reported a fourth-quarter net loss that widened to $49.5 million, or 53 cents a share, from $21.7 million, or 28 cents a share, in the year-ago period, wider than the FactSet consensus for a per-share loss of 44 cents. Revenue fell 36.5% to $21.8 million, topping the FactSet consensus of $20.7 million. The stock has lost 55.1% over the past 12 months, while the iShares Nasdaq Biotechnology ETF has climbed 40.2% and the S&P 500 has advanced 32.4%.

ATNX stock: over 50% plunge on March 1, 2021

Yahoo -> Finance -> Conversation 

This company's market cap just got cut from 1.25 Billion to 535 million, with revs of 156 million and 2.45 per share in cash. Oh yeah, its going back up.

no worries~ they have 410asset, 324M current asset, quick ratio 3.49, current ratio 3.49, 102 M annual revenue

A complete overreaction. And FDA approval was not excepted. They have already a fda approval drugs from last month. The The stock is at least worth 8-9$without oral p. From this level I am bullish. I hedge my self with 10% short before the weekend. It is covered now and i did got more shares at 5.05. Suddenly break even at 6.5 again! 

Dr. Wu Yaojun - Advisor Prof. Shi xizhi

 1 9 9 6 年1 0 月2 5 日。南京航空航天大学测试工程的一间普通教室里，一位留着平头，戴着深色眼镜，面容清癯的年轻人站在讲台上。他的面前除了一本厚厚的博士论文集，还有一根发黑的拐杖。
　　这里正在进行一场博士论文答辩，素来爱挑剔的老教授们不时地报以热烈的掌声。这位拄着拐仗作博士论文答辩的年轻人，就是我国第一位自学成才的残疾人博士后吴耀军。
　　出生7 个月，一场病魔夺去了吴耀军一条健康的腿。童年的不幸和寂寞也把自强不息的精神深深烙印在幼小的心灵谷底。
　　3 3 年前的一个黄昏，江苏省丹阳市农村一个普通农家小院，一条新生命打破了小院往日的宁静。小耀军长到了7 个月，有一天突然哭闹不止。医生诊断是脑膜炎( 后被确认为误诊) ，结果落下小儿麻痹症。望着尚在襁褓中嗷嗷待哺的残腿儿子，父母哭成了泪人，儿子以后的路该怎么走呵! 8 岁，到了读书年龄。同村小伙伴唱着《读书郎》蹦蹦跳跳地上了学堂，可他却没有这个“权利”，躺在病床上的小耀军，撕打着床上的衣物，哭喊着非要上学，读书似乎是他与生俱来的情结。父母亲都是斗大字不识一个的庄稼汉，他们又何尝没有想过送儿子进学堂? 在村小学的一间教室里，正书声琅琅。窗外，一个拄着拐杖的孩子伸长了脖子，倚着窗台往教室里探头。他紧紧盯着教室的黑板，担心漏掉一个字、一道题，他没有书本笔墨，只好靠一根拐杖支撑着沉重的躯体，用脑子强记黑板上的内容。下课的铃声响了，他重重跌倒在台阶上。终于，在一个雨天，这位满身泥水，一脸泪水、汗水的残疾孩子瞒着父母，斗胆推开教室的大门，“啪嗵”一声跪下了：“老师，求求您收下我吧，我要读书! ”执拗的小耀军用一颗泯灭不掉的渴望读书的心，感染了学校所有的老师，也感染了为他整日担惊受怕的父母。学校破例收下了这位拄拐杖的特殊学生。
　　然而，生活并没有因他的不幸而怜悯他。由于长时间倚着拐杖走山路，小耀军细嫩的腋窝，被磨破、磨肿。钻心的疼痛，再无法使用单拐支撑身体重心。为了求学，不耽搁每天的课程，他干脆丢下单拐，爬着去上学。路上的碎石一次一次刮破他的膝盖和肘部。一天，当伤痕累累的吴耀军爬进教室时，学校水泥地上留下了一条几米长的血路! 在小耀军的每学期家庭报告书中，年年都记载着“三好学生”的印记。1 9 7 6 年9 月，吴耀军以优异的成绩考上了县立重点中学，成为全乡唯一的秀才。
　　初中3 年，吴耀军不仅自学完了高中全部课程，而且还学习了大学数学的一部分课程，还利用业余时间，学会了英语、俄语和德语三国语言，并且自学了计算机应用技术。
　　然而，命运并没有垂青这位天资聪明、意志坚强的孩子。
　　初中毕业，吴耀军以优异的成绩考上了无锡某中专学校。或许是世俗的偏见，拖着一条残腿的吴耀军最终没能跨进学校的大门，但他从没放下心爱的书本。1 9 8 1 年，信心十足的吴耀军走进高考的考场，结果以高出录取分数线3 0 多分的成绩考入南京某全国重点大学。同样因为身体的原因，再次被拒之门外。此时此刻，他明白，命运的无常和叵测是无法预测的，自己的命运掌握在自己的手中，只有靠自己的孜孜以求，命运才会低头。
　　1 9 8 2 年初春，吴耀军当上了一名代课教师。吴耀军的化学知识基础好，并且自学了许多化工技术。因此，他在1 9 8 5 年夏天受命于危难之际，离开学校，到乡办有机化工厂担任了技术员。到工厂后不久，他发现产品因为技术含量低、市场小，导致了产品严重积压，工厂连年亏损。他建议转产，自己整天拄着拐杖坚守生产第一线，同工人一道解决技术上出现的道道难题。由于产品质量好，适销对路，半年不到，这个工厂就赢利近2 0 万元。随之，吴耀军被提升为技术科长，后来又担任了技术副厂长。1 9 8 8 年冬，在镇江出差时，吴耀军无意中从一份《光明日报》上发现一条消息：1 9 8 9 年全国将在具有大学同等学历的人员中招收一批硕士研究生。这条消息使他如获至宝。而这时候，离考研只有两个月时间。为了不影响同宿舍的工友休息，他每天晚上等别人睡觉后，拿着从别人那里借来的复习资料躲到厕所里，借着微弱的灯光苦读。由于光线太暗，为了离灯光更近些，他搬来两张板凳叠在一起，自己则高高在上捧读不已。
　　终于，一辆绿色的邮车将招生办的信送到他刚从车间出来、沾满油污的手里。打开信，他惊呆了，他怎么也不相信自学参加的考试成绩竟夺得本考区第一。随后，宁夏大学又给他寄来了赴银川参加复试的通知书。刻不容缓，吴耀军简单地收拾一些日常用品，按规定时间赶到银川参加复试。结果顺利通过，他太兴奋了。回到老家江苏，静候着大学录取通知书。就在这时，校方来信：因他是单腿残疾人，户口又在农村，不能被录取。闻此消息，吴耀军几乎晕倒过去。多舛的命运又一次戏弄了他。
　　求学之路，两次沉重的打击并没有击垮吴耀军的坚强意志，反而更触动了他发愤读书的激情。
　　他不相信悲剧总是这般重演。吴耀军开始上访。穿过北京西单那条狭长的老胡同，在国家教委吴耀军向人们讲述着一根拐杖单腿求学道路上的艰辛，向人们展示了那条残腿的曲折动人的经历。教委的有关领导被深深打动了，按照国家教委有关规定，吴耀军终于被录取为宁夏大学数学系硕士研究生。于是，一个只有初中文化水平的残疾青年，靠自学考上研究生，走上了大学的讲坛。
　　1 9 9 2 年7 月，吴耀军以优异成绩毕业，并获宁夏大学数学系硕士研究生学位。吴耀军回到阔别三载的故乡江苏镇江，走上了华东船舶工业学院的讲台。每天，他都要拄着拐杖艰难登上四楼为学生授课。一天两节课，一般健康的老师也会感到口干舌燥，很辛苦。而吴耀军每天要拖着一条残腿从楼下楼上又到三尺讲台，这里蕴含着怎样一种坚韧不拔的意志和“甘为人梯”的奉献精神啊! 大学生们深深地敬佩这位身残志坚的老师。在一次学校毕业典礼上，一位女大学毕业生给予他这样的评价：“吴老师身残志坚，他顽强的意志，认真严谨的治学态度，深深地感动着我们，鞭策影响着我们。他将永远地成为我们学习的楷模……”当上大学教师后，吴耀军的自学习惯仍然没有丢掉。在艰难的求索中，他又逐渐迷上了计算机图像处理，并产生了报考这个专业的博士生的想法。
　　考博士生的大部分考试课目没学过，复习时间却只有3 个月，同时他又一个人承担着9 0 多人的高等数学教学工作，工作已经够繁重了，其艰难可想而知。可是，从苦海里挣扎出来的吴耀军明知山有“虎”，偏向“虎”山行。夏日炎炎，江南多蚊虫。为了专心学习，穿着长裤、衬衫，仔细备好课，再自学，付出了常人难以想象的艰辛和努力。结果，他不仅圆满完成了全额教学任务，而且顺利地参加了博士生考试。
　　1 9 9 3 年1 2 月1 7 日，一封烫金的录取通知书终于飞到了吴耀军手里———他被南京航空航天大学1 4 系录取为博士生。
　　在南航大的两年多时间，吴耀军的学术道路经历了若干次转折，从硕士生的数学专业转到博士生的“测试计量技术与仪器”专业。这意味着他要在这两年半时间内掌握这个专业从本科到博研1 0 年的学习知识。而在博士生期间，因为研究课题的需要，他又先后转换了控制理论、智能结构、计算机仿真、力学、复合材料、现代非线前沿科学以及智能复合材料结构等多个学术领域，自学了3 0 多门课程，撰写了1 2 篇具有较高水平的学术论文，还参加了国家自然科学基金项目“采用神经网络的强度自适应复合材料结构研究”、航空科学基金
项目“智能复合材料飞机外形构件的研究”，提前半年完成了长达2 0 多万字的博士论文。天道酬勤，全班4 7 位博士生，吴耀军是唯一一个提前半年走到答辩台上的。
　　1 9 9 6 年1 1 月初，吴耀军如愿以偿，将到上海交通大学震动冲击噪声国家重点实验室做博士后。博士生毕业前夕，深圳一家公司曾开价8 0 0 0 元月薪“招募”他。用他自己的话讲，随便到南京市珠江路电脑一条街上找家电脑公司，一个月拿一两千元也应该没有问题，但吴耀军还是放弃了这些机会。当记者问及为什么继续留在清苦的学术界，吴耀军的回答是：“我们国家的总体科技水平还很落后，如果每个人都把自己的最大能力发挥出来的话，它的前进步伐将会快得多。国家培养我们走到这一步，我应该承包一些责任田。”雄心永驻，壮志弥坚。拄着拐杖的吴耀军，站在世界科技前沿领域里，又开始了艰难的跋涉。

Post Dr. Wu Yaojun - Advisor Prof. Shi xizhi

 【案例】吴耀军——中国第一个残疾人博士后

吴耀军，1963年出生在江苏省丹阳一个普通的农民家庭。三岁时得了小儿麻痹，从此残疾。耀军靠一根拐杖伴过了他孤独的童年，8岁上小学后，每次上学要翻过一座很高的山梁。一天来回两趟，他拄着拐杖的腋窝被磨擦得肿胀、破皮、流血。直到无法用拐杖了。但他从未放弃。从小学到初中，他的学习成绩一直是全班第一名。1978年7月，吴耀军以第一名的优秀成绩考了江苏省无锡市无线电中专学校。体检时因为残疾没有被录取。他克服重重困难，在家用3年时间自学完高中全部课程，自学完了德语、英语和俄语以及计算机应用技术。1982年7月，吴耀军充满信心地走进了高考考场，结果以超过录取分数线30分的好成绩考入了南京大学。因为残疾，吴耀军再次被拒绝在大学门外。1983年春他当上了中学的代课教师。从此一边教书，一边自学。1989年1月4日，吴耀军参加了研究生考试，以第一名的成绩考取了宁夏大学。但很快校方来信，因他是单腿残疾人，户口又在农村，不能被录取。他第三次被拒校门之外。不言败的吴耀军拄着拐杖去了北京，向国家教委领导讲述了自己的曲折经历解决了他的入学问题。1989年9月下旬，吴耀军一个只有初中文化水平的残疾青年靠自学，历经11年，成为宁夏大学数学系学生。他终于圆了大学梦。1992年7月，吴耀军硕士毕业后当上了华东船舶工业学院的教师，他一边教学，一边自学，1993年他考取了南京航空航天大学的博士生。在南航大学两年多的时间，他自学了30多门课程，撰写12篇具有较高水平的学术论文，提前半年完成了长达20多万字的博士论文。后来他又攻读博士后，1996年10月25日顺利通过了他的博士后评定。

TCDA stock: Kidney medicine | Later 2021 interim reading or update

March 1, 2021

Here is the article. 

Here are highlights:

1. one of two interim readouts expected in the second half of 2021 and the middle of 2022
2. While the FDA's denial of the appeal is certainly bad news for Tricida, the company still has a pathway to gain approval for veverimer.

What happened

Shares of Tricida (NASDAQ:TCDA) are down 30% at 1:33 p.m. EST today after the Food and Drug Administration denied the company's appeal of a complete response letter (CRL) that the agency issued for Tricida's marketing application for veverimer as a treatment for chronic kidney disease.

So what

A CRL, like the one Tricida received in August 2020, is essentially a rejection letter from the FDA with instructions on what data the agency would need to see for the drug to eventually get approved. Tricida was trying to get veverimer approved under the accelerated approval pathway, which uses surrogate endpoints, such as biomarkers, to predict clinical outcomes. In Tricida's case, it wanted to use change in serum bicarbonate levels to predict future kidney function in patients with chronic kidney disease.

Rather than address the issues and resubmit the marketing application with more clinical data, which would take awhile, Tricida appealed the FDA's decision, arguing that the change in serum bicarbonate seen in the one clinical trial run by the company was sufficient for accelerated approval.

Not surprisingly, the agency stuck with its belief that the magnitude of change in serum bicarbonate wasn't likely to predict clinical benefit in patients with chronic kidney disease. The agency is also concerned that a majority of the sites for the clinical trial were in Eastern Europe, where the different diets and treatments prescribed to patients might make the results less applicable to the U.S. patient population.

Now what

While the FDA's denial of the appeal is certainly bad news for Tricida, the company still has a pathway to gain approval for veverimer.

Tricida is currently running a second clinical trial, the Valor-CKD study, which theoretically could produce the data on changes in serum bicarbonate that the FDA wants. But Tricida warned that the data might not be strong enough for the agency to give veverimer an accelerated approval.

Fortunately, the Valor-CKD study is also measuring the function of patients' kidneys, so the results could be used for a full approval. Unfortunately for Tricida, it takes awhile for patients with chronic kidney disease to progress, so a final readout isn't expected until the first half of 2024. If veverimer works really well, the clinical trial could produce data during one of two interim readouts expected in the second half of 2021 and the middle of 2022.

TCDA stock: Analysts | 197.73% over next 12 months

March 1, 2021

Quick research: 

Wall Street is neutral on Tricida Inc (TCDA). On average, analysts give TCDA a Buy rating. The average price target is $15.333, which means analysts expect the stock to increase by 197.73% over the next twelve months.

That average ranking earns TCDA an Analyst Rating of 16, which is better than 16% of stocks based on data compiled by InvestorsObserver.

What's Happening With Tricida Inc Stock Today?

Tricida Inc (TCDA) stock is trading at $5.15 as of 11:15 AM on Friday, Feb 26, a drop of -$2.21, or -30.03% from the previous closing price of $7.36. The stock has traded between $4.85 and $5.59 so far today. Volume today is elevated. So far 1,960,142 shares have traded compared to average volume of 734,429 shares.